Menu

Experience

Kenneth Krisko

    • Reata Pharmaceuticals – $505 Million Follow-On Offering 


    • Therachon Sells to Pfizer for up to $810 Million 


    • Lodo Therapeutics Enters $970 Million Multi-Target Collaboration With Genentech 


    • Selecta Biosciences – $74 Million IPO 


    • AveXis – $95 Million IPO 


    • Cardioxyl Pharmaceuticals sale to Bristol-Myers Squibb 


    • Celyad Completes IPO 


    • NewLink Will License Ebola Vaccine to Merck 


    • Vitae Pharmaceuticals Completes Initial Public Offering  


    • FORMA $600 Million Collaboration with Celgene 


    • Eagle $50 Million Initial Public Offering 


    • Egalet Corporation IPO 


    • Genocea Biosciences IPO 


    • First US IPO of 2014 for GlycoMimetics 


    • TYRX: Acquired by Medtronic 


    • Two Independent Billion-Dollar Life Sciences Collaborations 


    • Apollo Endosurgery Agreement Acquire Obesity Intervention Division of Allergan 


    • Onconova Therapeutics IPO 


    • Epizyme, Inc. Initial Public Offering 


    • FORMA Therapeutics $200M Strategic Collaboration Deal with Celgene 


    • Cylex Use Chapter 11 Bankruptcy to Achieve Exceptional Sale Price 


    • Merus IPO – $61 Million 


Contact us

Back to top

© 2020 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.